Literature DB >> 18487007

The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses.

Stephen A Boorjian1, Paul L Crispen, Christine M Lohse, Bradley C Leibovich, Michael L Blute.   

Abstract

BACKGROUND: The origin of bilateral renal masses has not been definitively established to date. As limited studies on the genetics of bilateral tumors exist, defining the clinical behavior of these lesions remains important.
OBJECTIVE: To evaluate the impact of synchronous versus metachronous presentation on clinicopathological outcomes of patients with bilateral renal masses. DESIGN, SETTING, AND PARTICIPANTS: We identified 310 patients who were treated at the Mayo Clinic for sporadic bilateral renal masses between 1970-2003, including 148 (47.7%) with synchronous tumors and 162 (52.3%) with metachronous lesions. INTERVENTION: Patients underwent surgical resection of bilateral renal tumors. MEASUREMENTS: Clinicopathological features of synchronous and metachronous tumors were compared. Survival rates for patients with synchronous (n=92) and metachronous (n=100) renal cell carcinoma (RCC) were estimated using the Kaplan-Meier method and compared with the log rank test. RESULTS AND LIMITATIONS: Metachronous tumors had a greater degree of pathological concordance than synchronous lesions, with 87.7% of metachronous tumors representing bilateral RCC, compared to 69.2% of synchronous masses (p=0.002). Patients with synchronous RCC tended to have an increased incidence of papillary RCC compared to patients with metachronous RCC, who were more likely to have bilateral clear-cell RCC (p=0.076). A longer interval between tumors was inversely associated with the risk of cancer death for patients with metachronous RCC (HR 0.90, 95% CI 0.81-0.99, p=0.039). Compared to patients with metachronous RCC, patients with synchronous bilateral RCC had similar 10-yr CSS (70.5% vs. 69.4%, p=0.51) and OS (47.5% vs. 51.2%, p=0.58). We nevertheless recognize that these findings may be limited by the study's retrospective, single-institution design.
CONCLUSIONS: Metachronous bilateral solid renal masses have a greater degree of pathological concordance and were more likely to represent malignancy. Surgical resection may provide durable cancer control for patients with bilateral RCC, with no difference in survival noted between synchronous and metachronous cancers.

Entities:  

Mesh:

Year:  2008        PMID: 18487007     DOI: 10.1016/j.eururo.2008.04.079

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  13 in total

Review 1.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

2.  Outcomes of synchronous and metachronous bilateral small renal masses (< 4 cm): a population-based cohort study.

Authors:  Nissar Ahmed Sheikh; Mohammed Hassan Khan; Sanjay Pillai; Stephen Lang; Ghulam Nabi
Journal:  Int Urol Nephrol       Date:  2018-02-10       Impact factor: 2.370

Review 3.  Repeat partial nephrectomy: surgical, functional and oncological outcomes.

Authors:  Brian Shuch; W Marston Linehan; Gennady Bratslavsky
Journal:  Curr Opin Urol       Date:  2011-09       Impact factor: 2.309

4.  Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma.

Authors:  Paul L Crispen; Aldiana Soljic; Gregory Stewart; Alexander Kutikov; Daniel Davenport; Robert G Uzzo
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

5.  Bilateral synchronous sporadic renal masses: intermediate functional and oncological outcomes at a single institution.

Authors:  Benjamin Woodson; Raul Fernandez; Carrie Stewart; Sree Mandava; Liang Wang; Benjamin R Lee
Journal:  Int Urol Nephrol       Date:  2013-03-26       Impact factor: 2.370

6.  Management for patients with de novo or recurrent tumors in the residual kidney after surgery for nonfamilial bilateral renal cell carcinoma.

Authors:  Noboru Hara; Tsutomu Nishiyama; Norihiko Yoshimura; Satoshi Takaki; Kyoichiro Yamakado; Yasuo Kitamura; Kazuya Suzuki; Kota Takahashi
Journal:  Adv Urol       Date:  2009-11-30

7.  Developments in the surgical management of sporadic synchronous bilateral renal tumours.

Authors:  William T Lowrance; David S Yee; Alexandra C Maschino; Angel M Cronin; Melanie Bernstein; R Houston Thompson; Paul Russo
Journal:  BJU Int       Date:  2009-09-14       Impact factor: 5.588

8.  Partial nephrectomy in the setting of metastatic renal cell carcinoma.

Authors:  Kara N Babaian; Megan M Merrill; Surena Matin; Pheroze Tamboli; Nizar M Tannir; Eric Jonasch; Christopher G Wood; Jose A Karam
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

9.  Bilateral renal cancers: oncological and functional outcomes.

Authors:  Csaba Berczi; Ben Thomas; Zsolt Bacso; Tibor Flasko
Journal:  Int Urol Nephrol       Date:  2016-07-05       Impact factor: 2.370

10.  Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup.

Authors:  Eric A Singer; Srinivas Vourganti; Kelly Y Lin; Gopal N Gupta; Peter A Pinto; Ardeshir R Rastinehad; W Marston Linehan; Gennady Bratslavsky
Journal:  J Urol       Date:  2012-10-18       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.